WO2010105160A3 - Method of treating hematological malignancies and hematological neoplasms - Google Patents

Method of treating hematological malignancies and hematological neoplasms Download PDF

Info

Publication number
WO2010105160A3
WO2010105160A3 PCT/US2010/027144 US2010027144W WO2010105160A3 WO 2010105160 A3 WO2010105160 A3 WO 2010105160A3 US 2010027144 W US2010027144 W US 2010027144W WO 2010105160 A3 WO2010105160 A3 WO 2010105160A3
Authority
WO
WIPO (PCT)
Prior art keywords
agent
seq
peptide
actin
hematological
Prior art date
Application number
PCT/US2010/027144
Other languages
French (fr)
Other versions
WO2010105160A2 (en
Inventor
Debra K. Bowes
Allan L. Goldstein
Original Assignee
Regenerx Biopharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regenerx Biopharmaceuticals, Inc. filed Critical Regenerx Biopharmaceuticals, Inc.
Publication of WO2010105160A2 publication Critical patent/WO2010105160A2/en
Publication of WO2010105160A3 publication Critical patent/WO2010105160A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention relates to a method of treating hematological malignancies or hematological neoplasms in a subject, which comprises administering to a subject an effective amount of a peptide agent having actin-sequestering, actin-binding or actin-modulating peptide having a peptide motif as described herein, including the preferred motifs LKKTET (SEQ ID NO:10), KLKKTET (SEQ ID NO:25), LKKTETQ (SEQ ID NO:26) and LKKTNT (SEQ ID NO:11). Preferred peptides include TB4, a TB4 isoform, a TB4 N-terminal fragment, a TB4 C-terminal fragment, TB4ala, TB9, TB10, TB11, TB12, TB13, TB14, TB15, gelsolin, vitamin D binding protein (DBP), profilin, cofilin, adsevertin, propomyosin, fincilin, depactin, DNaseI, vilin, fragmin, severin, capping protein, β-actinin, acumentin, TB4 sulfoxide, lymphoid TB4 or a functional variant thereof, and others, and any combination thereof. The method optionally further comprises administering a second agent, which can be a stimulating agent that stimulates production of the peptide agent and/or at least one antineoplastic agent.
PCT/US2010/027144 2009-03-13 2010-03-12 Method of treating hematological malignancies and hematological neoplasms WO2010105160A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16002909P 2009-03-13 2009-03-13
US61/160,029 2009-03-13

Publications (2)

Publication Number Publication Date
WO2010105160A2 WO2010105160A2 (en) 2010-09-16
WO2010105160A3 true WO2010105160A3 (en) 2010-12-23

Family

ID=42729134

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/027144 WO2010105160A2 (en) 2009-03-13 2010-03-12 Method of treating hematological malignancies and hematological neoplasms

Country Status (1)

Country Link
WO (1) WO2010105160A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101746915B1 (en) 2014-03-11 2017-06-28 한양대학교 산학협력단 Diagnosis of Hematologic-oncologic diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004099768A1 (en) * 2003-05-05 2004-11-18 Regenerx Biopharmaceuticals, Inc. Method for detecting development of a physiological disorder in a subject
US20060246057A1 (en) * 2003-07-18 2006-11-02 Regenerx Biopharmaceuticals, Inc Treatment or prevention of damage due to radiation exposure

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004099768A1 (en) * 2003-05-05 2004-11-18 Regenerx Biopharmaceuticals, Inc. Method for detecting development of a physiological disorder in a subject
US20060246057A1 (en) * 2003-07-18 2006-11-02 Regenerx Biopharmaceuticals, Inc Treatment or prevention of damage due to radiation exposure

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEE ET AL.: "Thymosin Beta-10 Inhibits Angiogenesis and Tumor Growth by Interfering with Ras Function.", CANCER RESEARCH, vol. 65, 2005, pages 137 - 147 *
SHIMAMURA ET AL.: "Expression of the Thymosin Beta-4 Gene During Differentiation of Hematopoietic Cells.", BLOOD., vol. 76, 1990, pages 977 - 984 *

Also Published As

Publication number Publication date
WO2010105160A2 (en) 2010-09-16

Similar Documents

Publication Publication Date Title
WO2006090810A3 (en) Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
Mora et al. Intense degradation of myosin light chain isoforms in Spanish dry-cured ham
MX2009004147A (en) Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides.
AR064555A1 (en) WT1 PEPTIDE RESTRICTED TO HLA-A * 1101 AND PHARMACEUTICAL COMPOSITION THAT INCLUDES THE SAME
PE20121721A1 (en) PEPTIDE ANALOGUE OF OXYNTHOMODULIN
CY1111411T1 (en) ANALYSIS OF SINGLE-WITH-TIN-GLYCAGONY-Peptide-2 (GLP-2)
NZ597685A (en) Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
WO2006113681A3 (en) Plant-derived elastin binding protein ligands and methods of using the same
MX2011008759A (en) Means and methods for manufacturing highly pure neurotoxin.
Nongonierma et al. Strategies for the release of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides in an enzymatic hydrolyzate of α-lactalbumin
ES2849950T3 (en) Protease-resistant lipidated GLP-1 peptide analogs
WO2010007144A3 (en) Mutated netrin-4 proteins, fragments thereof and their uses as drugs
WO2012174397A3 (en) Anti-inflammatory pharmaceutical products
WO2010105160A3 (en) Method of treating hematological malignancies and hematological neoplasms
WO2008047370A3 (en) Compositions and methods for inducing angiogenesis
WO2006097432A3 (en) Keratin-binding desmoplakin polypeptide sequences
WO2008024195A3 (en) Methods and compositions for conserving and/or preparing an organ or tissue for transplant
WO2010011994A3 (en) Polypeptides and uses thereof
Karhu et al. Isolation of new ligands for orphan receptor MRGPRX1—hemorphins LVV-H7 and VV-H7
WO2010103515A3 (en) Compositions and methods for prevention and treatment of neurodegenerative diseases
WO2011135222A3 (en) Use of peptides as transporters intended for the internalization of molecules of interest into target cells
WO2005004894A3 (en) Methods for increasing cell and tissue viability
WO2007014199A3 (en) Tfpi fragments as anti-microbial agents
HK1131162A1 (en) Cytokine derivatives
WO2007101948A3 (en) Novel vaccines for treating or preventing infections by parasites of the family taenidae and in particular of the genus echinococcus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10751475

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10751475

Country of ref document: EP

Kind code of ref document: A2